To find out the plausible clinical significance of these results, we investigated associations between elevated expression levels of CD3E, CD4, CD8A, CD19, NCAM1 (gene for CD56), PDCD1 (gene for PD-1), HAVCR2 (gene for TIM-3), LAG3, TIGIT, and ICOS genes with clinical parameters including disease-specific survival (DSS), overall survival (OS), and progression-free interval (PFI) from TCGA datasets of CRC patients (Figure 5). This evidence concerns the gene CD19 and colorectal carcinoma.